Detailed price information for Shoulder Innovations Inc (SI-N) from The Globe and Mail including charting and trades.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback